Sanofi Chief Digital Officer Emmanuel Frenehard on scaling AI across a Big Pharma global enterprise and why a strategy of ...
Novartis filed New Jersey notices for 322 East Hanover layoffs starting October 2, after earlier filings for 76 cuts at the same site. Disclosures to date do not specify impacted functions, job ...
Modern biopharma firms are adapting their R&D investment strategies in response to challenges such as the impending $300 ...
A joint framework is being built to convert Israeli academic target biology into viable small-molecule programs by integrating AI-enabled design with rigorous experimental validation. ChemPass AI™ ...
Chemomab and Scipher Medicine agreed to merge in an all-stock deal to advance an anti-CCL24 antibody into an AI-guided Phase II rheumatoid arthritis trial, while Teva struck a global licensing deal ...
Bansi Nagji, CEO of PANTHERx Rare, explores how innovation is increasingly directed toward rare and orphan diseases, driven ...
In today's Pharmaceutical Executive Daily, Vertex Pharmaceuticals announces a $10 billion acquisition of Crinetics ...
Zymeworks will pay $17.00/share (~$929M) for Theravance, prioritizing Yupelri-linked profitability and planned post-close ...
Novartis is buying Myricx to internalize an NMTi-based ADC payload platform intended to expand ADC applicability and ...
It was a jarring experience that stemmed from a startlingly common misconception: that adults don't get T1D; however, she is ...
Transaction terms include $85-per-share all-cash consideration (~$10B enterprise value) and an anticipated Q3 2026 close, contingent on customary conditions. Portfolio fit emphasizes serious, ...
For pharmaceutical executives, the transition from just extending to fully optimizing life is a defining commercial ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results